美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Dova Pharmaceuticals Inc.

28.04

0.0000

成交量：- -

成交額：- -

市值：8.08億

市盈率：-10.95

高：28.04

開：28.04

低：28.04

收：28.04

52周最高：28.54

52周最低：5.62

股本：2,880.19萬

流通股本：933.84萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.5607

每股收益(LYR):-2.5998

淨資產收益率：-90.08%

總資產收益率：-39.36%

市淨率：15.90

市盈率(LYR):-10.79

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Dova Pharmaceuticals Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.dova.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Dova製藥有限公司最初以PBM AKX Holdings，LLC命名成立，是一家根據特拉華州法律於2016年3月24日成立的有限責任公司。該公司是一家專註於獲得，開發和商業化專業醫生治療疾病的候選藥物的製藥公司，最初的重點是解決血小板減少症，一種以低血小板計數為特徵的疾病。他們從Eisai，Inc.或Eisai於2016年3月獲得的候選藥物avatrombopag是口服血小板生成素受體激動劑或TPO-RA，它們正在開發用於治療血小板減少症。該公司最近完成了兩項相同設計的關鍵的3期臨床試驗，該臨床試驗評估了avatrombopag用於治療慢性肝病或CLD患者的血小板減少症，其經歷了不發生於微創至中等程度的微創醫療程序。 Avatrombopag在這些具有高統計學意義的臨床試驗中遇到主要和次要終點。根據這些結果，計劃在2017年第三季度向美國食品和藥物管理局（FDA）提交新的藥物申請或NDA，以提供初步指示。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/DOVA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DOVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DOVA\",,,,,undefined,":{"symbol":"DOVA","market":"US","secType":"STK","nameCN":"Dova Pharmaceuticals Inc.","latestPrice":28.04,"timestamp":1573506000000,"preClose":28.04,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":9338364,"shares":28801863,"eps":-2.560714,"marketStatus":"停牌","change":0,"latestTime":"02-25 11:22:38 EST","open":28.04,"high":28.04,"low":28.04,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.560714,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1772053200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1498708800000,"exchange":"NASDAQ","adjPreClose":28.04,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DOVA\",,,,,undefined,":{"symbol":"DOVA","floatShares":9338364,"roa":"-39.36%","roe":"-90.08%","lyrEps":-2.599775,"shares":28801863,"dividePrice":0,"high":28.04,"amplitude":0,"preClose":28.04,"low":28.04,"week52Low":5.62,"pbRate":"15.90","week52High":28.54,"institutionHeld":0,"latestPrice":28.04,"eps":-2.560714,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.560714,"open":28.04,"prevYearClose":28.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DOVA\",params:#limit:5,,,undefined,":[{"date":"2019-08-06","symbol":"DOVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.57,"defaultRemindTime":1565078400000,"name":null,"time":"盤前","dateTimestamp":1565064000000,"actualEps":-0.7},{"market":"US","date":"2019-03-05","symbol":"DOVA","fiscalQuarterEnding":"2018/12","expectedEps":-0.77,"name":null,"time":"盤前","type":"earning","dateTimestamp":1551762000000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2018-11-08","symbol":"DOVA","fiscalQuarterEnding":"2018/09","expectedEps":-0.82,"name":null,"time":"盤後","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"post","actualEps":-0.69},{"market":"US","date":"2018-08-09","symbol":"DOVA","fiscalQuarterEnding":"2018/06","expectedEps":-0.58,"name":null,"time":"盤後","type":"earning","dateTimestamp":1533787200000,"reportTimeType":"post","actualEps":-0.7},{"market":"US","date":"2018-05-09","symbol":"DOVA","fiscalQuarterEnding":"2018/03","expectedEps":-0.45,"name":null,"time":"盤後","type":"earning","dateTimestamp":1525838400000,"reportTimeType":"post","actualEps":-0.52}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DOVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DOVA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.dova.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Dova製藥有限公司最初以PBM AKX Holdings，LLC命名成立，是一家根據特拉華州法律於2016年3月24日成立的有限責任公司。該公司是一家專註於獲得，開發和商業化專業醫生治療疾病的候選藥物的製藥公司，最初的重點是解決血小板減少症，一種以低血小板計數為特徵的疾病。他們從Eisai，Inc.或Eisai於2016年3月獲得的候選藥物avatrombopag是口服血小板生成素受體激動劑或TPO-RA，它們正在開發用於治療血小板減少症。該公司最近完成了兩項相同設計的關鍵的3期臨床試驗，該臨床試驗評估了avatrombopag用於治療慢性肝病或CLD患者的血小板減少症，其經歷了不發生於微創至中等程度的微創醫療程序。 Avatrombopag在這些具有高統計學意義的臨床試驗中遇到主要和次要終點。根據這些結果，計劃在2017年第三季度向美國食品和藥物管理局（FDA）提交新的藥物申請或NDA，以提供初步指示。","exchange":"NASDAQ","name":"Dova Pharmaceuticals Inc.","nameEN":"Dova Pharmaceuticals Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DOVA\",market:\"US\",,,undefined,":null}}